Your Hearts, Your Scars
Reflective and forthright, Adina Talve-Goodman’s posthumously published essay collection Your Hearts, Your Scars discusses chronic illness, the corporeal body, and the privilege of being alive.
Talve-Goodman was born with congenital heart issues, went into heart failure at the age of twelve, and was put on the transplant list at seventeen. Two years later, she received a new heart. She had eleven years of good health and no complications before being diagnosed with a rare lymphoma caused by her post-transplant immunosuppressant drugs. In her essays, she muses on disabilities, the fallibility of the human body, intimacy and vulnerability, faith, health, medicine, and love—and the intersections between these factors. Acutely aware that she is alive because someone else is not, she tries to untangle the threads of what this means while also remaining aware of how others in the transplant community cope.
Some of the essays represent separate drafts that were combined after Talve-Goodman’s death. As a rule, their prose is sharp and incisive, if occasionally overly self-aware. Talve-Goodman avoids self-pity and pandering for sympathy to relay events in matter-of-fact, wry terms. Still, despite their personal nature, the essays don’t betray much of Talve-Goodman’s personality. They are shared from a distance and seem almost wary of the impact that their words might have.
Illustrating the complex experience of organ transplantation and chronic illness, the essays of Your Hearts, Your Scars exist in the liminal spaces between health and sickness and between living and dying. They explore what it means to be alive, to have a body, and to come back from the brink of death.
Reviewed by
Jaime Herndon
Disclosure: This article is not an endorsement, but a review. The publisher of this book provided free copies of the book to have their book reviewed by a professional reviewer. No fee was paid by the publisher for this review. Foreword Reviews only recommends books that we love. Foreword Magazine, Inc. is disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255.
